Nivolumab

A subcutaneous nivolumab formulation showed noninferior pharmacokinetics and objective response rates compared with IV nivolumab in patients with advanced or metastatic clear cell renal cell carcinoma, according to the agent’s manufacturer.

MADRID — The addition of nivolumab to neoadjuvant chemotherapy, followed by adjuvant nivolumab, improved outcomes for patients with untreated resectable non-small cell lung cancer, randomized phase 3 study results showed.

The FDA approved nivolumab as adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma, according to the agent’s manufacturer.

The addition of nivolumab to neoadjuvant chemotherapy followed by adjuvant nivolumab extended EFS among patients with resectable non-small cell lung cancer, according to the agent’s manufacturer.

The combination of ipilimumab and nivolumab extended PFS compared with ipilimumab alone as second-line therapy for patients with advanced melanoma resistant to PD-1 inhibitors, according to study results published in Nature Medicine.

Today is World Lung Cancer Day.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Opdivo for melanoma treatment in patients aged 12 years and older, according to a Bristol Myers Squibb press release.

The addition of nivolumab to cisplatin-based chemotherapy improved outcomes compared with standard regimens for certain patients with advanced urothelial carcinoma, according to the agent’s manufacturer.

More than one-third of adults with previously untreated stage III non-small cell lung cancer exhibited a pathologic complete response after receiving perioperative nivolumab plus chemotherapy, results of a randomized phase 2 trial showed.

CHICAGO – Cabozantinib plus nivolumab showed promising efficacy in patients with papillary, unclassified or translocation-associated renal cell carcinoma, according to updated phase 2 study results presented at ASCO Annual Meeting.